ReviewReviews in endocrine & metabolic disorders2017
Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.
Review in Reviews in endocrine & metabolic disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2019Pooled it
- Pediatric osteoporosis: a comprehensive imaging-based review of diagnosis, differential diagnosis, and etiology.Skeletal radiology · 2026Review
- Hyperparathyroidism revealed by brown tumors of the jaws: a retrospective case series.International journal of surgery case reports · 2026Article
- Overcoming Stability Challenge During the Quantification of SHR6508 in Human Plasma by LC-MS/MS.Biomedical chromatography : BMC · 2026Article
- Association Between Serum Parathyroid Hormone Levels and Femoral Bone Mineral Density in Patients with Chronic Kidney Disease Stage 3.Journal of clinical medicine · 2026Article
- Association Between the Uric Acid-to-Creatinine Ratio and Elevated Parathyroid Hormone Levels in Adults Without Known Parathyroid Disease.Journal of clinical medicine · 2026Article
- Challenges and unmet needs of [European journal of nuclear medicine and molecular imaging · 2026Article
- Serum-free culture with PVP enables maintenance of primary culture of parathyroid cells in vitro.Bioscience reports · 2026Article
- MR Pulse Sequences for Parathyroid Adenoma Imaging Using [Nuclear medicine and molecular imaging · 2026Article
- Early endocrine, bone, and inflammatory responses to microwave ablation for hyperparathyroidism: preliminary study.Frontiers in endocrinology · 2026Article
- A patient with CKD complicated by secondary hyperparathyroidism and parathyroid carcinoma: a case report.Frontiers in medicine · 2026Article
- Correlation between parathyroid volume and calcium and phosphorus metabolism in maintenance hemodialysis patients based on Doppler ultrasound technology.International urology and nephrology · 2025Article
- Review
- Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study.BMC nephrology · 2025Article
- Osteoporosis and Normocalcemic Primary Hyperparathyroidism (Conservatively or Surgically Managed).Journal of clinical medicine · 2024Review
- [MiR-301a-5p modulates parathyroid hormone secretion in secondary hyperparathyroidism possibly by regulating calcium-sensing receptor].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification.Journal of cardiovascular development and disease · 2023Review
- Anaesthetic considerations in Shrinking Man syndrome: two case reports.BMC anesthesiology · 2023Article
- Article
- Secondary Hyperparathyroidism Presenting as a Brown Tumor: A Case Report and Review of the Literature.Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uremic secondary hyperparathyroidism is a multifactorial and complex disease often present in advanced stages of chronic kidney disease. The accumulation of phosphate, the increased FGF23 levels, the reduction in active vitamin D production, and the tendency to hypocalcemia are persistent stimuli for the development and progression of parathyroid hyperplasia with increased secretion of PTH. Parathyroid proliferation may become nodular mainly in cases of advanced hyperparathyroidism. The alterations in the regulation of mineral metabolism, the development of bone disease and extraosseous calcifications are essential components of chronic kidney disease-mineral and bone disorder and have been associated with negative outcomes. The management of hyperparathyroidism includes the correction of vitamin D deficiency and control of serum phosphorus and PTH without inducing hypercalcemia. An update of the leading therapeutic tools available for the prevention and clinical management of secondary hyperparathyroidism, its diagnosis, and the main mechanisms and factors involved in the pathogenesis of the disease will be described in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.